Intuitive Surgical stock gains as analysts back strong Q2 growth
Published on 09/19/2026 at 11:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical stock (ISIN US46120E6023) opened at USD 393.33 on September 18, 2026 on Nasdaq, with investors weighing a strong second quarter marked by double-digit revenue and procedure growth alongside rich valuation multiples. As MarketBeat reported on September 19, 2026, brokerages assign the shares an average 12-month price target of USD 508.68, underlining sustained confidence in the company’s surgical robotics platform despite a sizeable year-to-date drawdown.
Q2 2026 delivers strong revenue and procedure growth
According to an economic moat analysis by StockIntent, Intuitive Surgical generated USD 2.89 billion in revenue in Q2 2026, representing 19% growth versus the prior-year quarter and supported by a 70.0% non-GAAP gross margin. In the same period, non-GAAP earnings per share came in at USD 2.80, with worldwide procedures growing approximately 16% year over year and da Vinci procedures up roughly 15%, while Ion bronchoscopic procedures accelerated at approximately 36%, illustrating broad-based demand across the company’s platforms.
The Q2 2026 performance built on a strong start to the year. Instruments and accessories contributed USD 1.73 billion of the USD 2.89 billion Q2 2026 revenue, close to three fifths of the total, while the company collected about USD 1,830 of instruments and accessories revenue per da Vinci procedure in Q2 2026, up around USD 30 from roughly USD 1,800 a year earlier, as highlighted by a detailed analysis on Yahoo Finance. By comparison, Q1 2026 revenue per procedure was higher at approximately USD 1,880, a USD 100 year-over-year increase from about USD 1,780, with management attributing the sequential USD 50 pullback largely to unusually strong customer ordering patterns in the first quarter.
Installed base expansion and guidance underpin long-term story
In terms of capacity, Intuitive Surgical’s installed base reached 11,710 systems in Q2 2026, up 12% year over year, according to StockIntent. This expansion supports the company’s medium-term outlook, with management guiding for worldwide da Vinci procedure growth of 13.5% to 15.5%, a range that reflects expectations for continued adoption in general surgery, urology and gynecology as well as emerging indications.
From an investor’s perspective, the revenue and procedure growth trends interact with valuation and sentiment. An overview of the medical diagnostics sector by Investing.com notes that Intuitive Surgical’s revenue has accelerated from USD 5.7 billion to USD 10.1 billion over the past five years, while the company maintains a near-30% net margin, underscoring the strength of its economic moat even as the stock has experienced meaningful multiple compression.
Analysts maintain Moderate Buy amid valuation reset
Broker sentiment provides an important counterweight to the recent share price weakness. As MarketBeat summarizes, Intuitive Surgical currently holds an average rating of Moderate Buy from brokerages, with the consensus 12-month price target standing at USD 508.68. Within that framework, Leerink Partners cut its price target from USD 573.00 to USD 454.00 in a research note dated July 17, 2026, while retaining an outperform stance, reflecting both recognition of valuation risk and ongoing confidence in the company’s competitive position.
The same MarketBeat overview notes that shares opened at USD 393.33 on the latest trading day covered, with Intuitive Surgical’s twelve-month low at USD 328.57 and its twelve-month high at USD 603.88. This places the current level roughly 30% below the peak, consistent with the -30.6% year-to-date performance cited by Investing.com, where the stock is described as a quality alternative for investors willing to pay a premium for market-leading surgical robotics exposure.
Technical signals highlight choppy conditions
Shorter-term trading signals underline that the path back toward analyst targets may be volatile. A quantitative signal analysis from StockTradersDaily, dated September 19, 2026, identifies a mid-channel oscillation pattern in Intuitive Surgical shares and lists key signals at USD 323.39, USD 378.55, USD 393.33 and USD 433.29, with USD 393.33 marked as the current price level. The analysis points to a 50.2:1 risk-reward setup targeting a 14.5% gain versus 0.3% risk in a position-trading strategy, while also highlighting divergent sentiment across near-term, mid-term and long-term horizons, suggesting that choppy trading conditions could persist.
Against this backdrop, investors must weigh robust fundamentals and supportive analyst targets against short-term technical resistance and broader sector dynamics. In the medical diagnostics sector overview, Investing.com notes that large-cap diagnostics equipment names such as Intuitive Surgical have faced significant multiple compression, with the stock down -30.6% year to date from a USD 603 peak to USD 393.20 as of September 18, 2026, even though the article characterizes the selloff as sentiment-driven rather than reflective of deteriorating fundamentals.
Stock trades well below its 12-month high
Intuitive Surgical stock remains considerably below its twelve-month high despite the recent uptick. Per MarketBeat, the shares opened at USD 393.33 on the most recent covered trading day, against a twelve-month high of USD 603.88 and a twelve-month low of USD 328.57. In sector context, Investing.com cites a trading level of USD 393.20 as of September 18, 2026, which aligns closely with the MarketBeat snapshot and underlines that the stock currently trades roughly one third below its recent peak despite the company’s high margins and accelerating revenue base.
Intuitive Surgical stock - key data
- Company: Intuitive Surgical, Inc.
- ISIN: US46120E6023
- Ticker: ISRG
- Trading venue: Nasdaq
- Price (as of September 18, 2026): 393.33 USD
- Sector / Industry: Health Care Equipment
- Index membership: S&P 500
